Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Rani Therapeutics Holdings Inc

RANI ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.80

▼ -0.23%

Market Cap $110.97M · Vol 66.16K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$110.97M

Micro Cap

Div Yield

N/A

EPS Growth

+58.89%

YoY

RSI (14)

47.19

Momentum

Beta

0.69

vs Market

52W High

$3.87

79.43% below

52W Low

$0.44

80.56% above

Volume

66.16K

Avg 105.09K

P/B

3.99

Price-to-book

ROE

N/A

Return on equity

Free Float

94.96%

Public shares

Shariah Compliance8 STANDARDS

✗ Rani Therapeutics Holdings Inc (RANI) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RANI pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.52%

+22.67%

-28.28%

-35.80%

YTD

-41.03%

+42.98%

-81.40%

-95.72%

Financials & Valuation

TTM · Annual

Total Revenue	$1.63M
Net Income	$-40,950,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-2,345.99%
Net Profit Margin	-2,507.65%
ROE	N/A
ROA · ROIC	-85.98% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	54.68
P/B	3.99
P/FCF	N/A
EPS Growth	+58.89%
Outstanding Shares	139.40M

Technical Indicators

50-Day SMA	$0.77
200-Day SMA	$1.17
RSI (14)	47.19
Beta	0.69
52-Week High	$3.87
52-Week Low	$0.44

Volume Today	66.16K
Avg Daily Volume (30D)	105.09K
Relative Volume	0.63x
Volatility (10D)	36.62
Volatility (30D)	95.02
Free Float	94.96%

Analyst Consensus

BUY

Current Price $0.80

Mean Target $7.50

52W Low$0.44 52W High$3.87

Current

Target

$0.44 $3.87

Current Analyst target

+842.09% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG011R6PZZ0

ISINUS7530181004

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).